On June 26th, a unique medical innovation ceremony - "Celebrating the 104th Anniversary of the Founding of the Communist Party of China with Technological Innovation · Ruijin Hospital Science and Technology Innovation Week" - was grandly held in the Jiading Campus of Ruijin Hospital. At the ceremony, the second phase of Ruijin Hospital Jiading Campus, a national medical center construction project, was officially launched, marking a milestone step for this century old hospital in serving national strategies and promoting the expansion and sinking of high-quality medical resources.

At the ceremony, Ruijin Hospital showcased a batch of innovative achievements with significant clinical value. These scientific research achievements derived from clinical pain points and serving clinical needs vividly illustrate the hospital's translational medicine development path of "coming from clinical practice and going to clinical practice". Vice President Bi Yufang, on behalf of Ruijin Hospital, signed transformation cooperation agreements with six outstanding enterprises in the industry. This signing covers multiple fields such as in vitro diagnostic reagents, innovative medical devices, innovative drug research and development, and health management products, which will bring substantial breakthroughs to improve the level of diagnosis and treatment and improve patient prognosis. Dunwill Medical, as the representative of the original research mark external diagnostic product conversion enterprise, signed a conversion cooperation agreement on stage. Among them, Professor Zhao Weili's team from the Hematology Research Institute of Ruijin Hospital has independently transformed their intellectual property rights, and the innovative transformation result developed by Dunwill Medical has been officially unveiled - the four types of microRNA detection kits for diffuse large B-cell lymphoma (digital PCR method).

The markers for four types of microRNA detection kits (digital PCR method) are derived from the original research of Professor Zhao Weili's team at the Institute of Hematology, Ruijin Hospital. The research results were published in the internationally authoritative journal Molecular Oncology in tumor molecular biology, and have obtained the authorization announcement for the national invention patent "miRNA combination and its application in the preparation of prognostic markers for DLBCL" (CN111909999B).

This kit is used for in vitro quantitative detection of the expression of four types of microribonucleic acids, miR21, miR130b, miR155, and miR28, in human serum. It is suitable for evaluating the recurrence risk of newly diagnosed and untreated diffuse large B-cell lymphoma patients, and positive test results are associated with poor patient prognosis. This product is currently in the preparation stage for the registration of Class III medical devices by the National Medical Products Administration. In the future, the successful registration of this product will achieve two major innovations: indication innovation, which will be the first in class of its kind in blood tumor diagnosis products, filling the clinical application gap; Innovative in vitro diagnostic product category, the first in class microribosomal nucleic acid detection product in blood tumor diagnosis products, filling the gap in related products. It provides strong support for the diagnosis and screening of complex and difficult to treat diffuse large B-cell tumors, demonstrating the demonstration effect of collaborative innovation between medical research enterprises.

The four types of microRNA detection kits (digital PCR method) are also Dunwill Medical's first attempt to transform the field of view of original biomarkers from solid tumors to blood tumors, following the seven types of microRNA detection kits for liver cancer. This is also Dunwill Medical's expansion of its self-developed TERIFAQ (Target Enriched RNA Isolation for Amplification & Quantification) microRNA detection underlying technology to new miRNA diagnostic product applications. The successful implementation of the diffuse large B-cell lymphoma detection kit once again confirms the strong R&D and clinical translation capabilities of Dunwill Medical based on the "medical research production" integrated full process closed-loop solution, which will continue to empower the development of precision medicine.